ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Delores Esparza President Elect Of ONS; Brown Demands Jako Retract “Insulting Remarks”

May 13, 1988

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

Seattle Cancer Care Alliance Marks its 10th Anniversary—January 2011

June 28, 2021

Litton Awarded $342,618 For Frederick Fee

February 21, 1975

Golde To Step Down At MSK; Porter Joins Hogan & Hartson.

January 26, 2001

Did ACS Flip-Flop On Stem Cell Research? Society Says No, Patient Coalition Says Yes

September 10, 1999